Concepedia

High-throughput Developability Screening

High-Throughput Developability Screening is a systematic method that enables the rapid evaluation of multiple biopharmaceutical candidate molecules through standardized assays to assess their developability characteristics, distinguishing it from low-throughput or targeted screening approaches by its capacity for parallel, large-scale analysis.

4

Publications

366

Citations

36

Authors

9

Institutions

Publications per year

2017–2026

2

Parents

Publications

4

Developability Index: A Rapid In Silico Tool for the Screening of Antibody Aggregation Propensity

Timothy M. Lauer, Neeraj J. Agrawal, Naresh Chennamsetty et al. · Journal of Pharmaceutical Sciences · 2011 · 215 citations

, , +15

High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice

Ryan L. Kelly, Tingwan Sun, Tushar Jain et al. · mAbs · 2015 · 93 citations · Full text

, , +17

Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids

Marc Oeller, Ryan Kang, Hannah L. Bolt et al. · Nature Communications · 2023 · 34 citations · Full text

, , +17

High-throughput developability assays enable library-scale identification of producible protein scaffold variants

Alexander W. Golinski, Katelynn M. Mischler, Sidharth Laxminarayan et al. · Proceedings of the National Academy of Sciences · 2021 · 24 citations · Full text

, , +17

Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

Tushar Jain, Bianka Prinz, Alexander Marker et al. · mAbs · 2024 · 15 citations · Full text

, , +15

1–5 of 4

Authors

36

  1. AN
    Antonios Nikitidis

    AstraZeneca (Sweden), Sweden

    1 publications · 34 citations

    1

    h-index

  2. NC
    Naresh Chennamsetty

    Massachusetts Institute of Technology, United States

    1 publications · 215 citations

    1

    h-index

  3. PZ
    Pavol Zlatoidský

    State Institute for Drug Control, Slovakia

    1 publications · 34 citations

    1

    h-index

  4. IC
    Isabelle Caffry

    Adimab (United States), United States

    1 publications · 93 citations

    1

    h-index

  5. KM
    Katelynn M. Mischler

    University of Minnesota, United States

    1 publications · 24 citations

    1

    h-index

1–5 of 36

Institutions

9

  1. Massachusetts Institute of Technology

    Cambridge, United States

    2 h-index

    6 publications

    1K citations

  2. University of Cambridge

    Cambridge, United Kingdom

    1 h-index

    4 publications

    136 citations

  3. Max Planck Institute of Biochemistry

    Martinsried, Germany

    1 h-index

    1 publications

    34 citations

  4. AstraZeneca (Sweden)

    Södertälje, Sweden

    1 h-index

    6 publications

    204 citations

  5. Palo Alto Institute

    San Mateo, United States

    1 h-index

    2 publications

    186 citations

  6. Adimab (United States)

    Lebanon, United States

    1 h-index

    9 publications

    837 citations

  7. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    1 h-index

    2 publications

    68 citations

  8. Novartis (Switzerland)

    Basel, Switzerland

    1 h-index

    2 publications

    430 citations

1–8 of 9

Venues

  1. Proceedings of the National Academy of Sciences

    PNAS · 1 publications · 24 citations

    1

    h-index

  2. Nature Communications

    1 publications · 34 citations

    1

    h-index

  3. mAbs

    1 publications · 93 citations

    1

    h-index

  4. Journal of Pharmaceutical Sciences

    1 publications · 215 citations

    1

    h-index

1–4